Transcatheter closure of secundum atrial septal defect

Shimpo, Hideto; Hojo, Reina; Maeshiro, Ryo; Konuma, Takeshi; Tempaku, Hironori

doi:10.1007/s11748-013-0268-7

Cited by 4 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adverse events rate of 11.9% after percutaneous device closure in our study is in line with or slightly higher than other studies. [25][26][27] We have used a definition of adverse events applicable to a previous study, which facilitates comparison between studies. 23 The definition of adverse events is wider in ours and in the study by Bartakin et al than is generally applied, which may explain the slightly increased frequency of adverse events following percutaneous closure compared to some other studies.…”

Section: Discussionmentioning

confidence: 99%

Adverse events within 1 year after surgical and percutaneous closure of atrial septal defects in preterm children

et al. 2019

View full text Add to dashboard Cite

Introduction:Atrial septal defect is the third most common CHD. A hemodynamically significant atrial septal defect causes volume overload of the right side of the heart. Preterm children may suffer from both pulmonary and cardiac comorbidities, including altered myocardial function. The aim of this study was to compare the rate of adverse events following atrial septal defect closure in preterm- and term-born children.Method:We performed a retrospective cohort study including children born in Sweden, who had a surgical or percutaneous atrial septal defect closure at the children’s hospitals in Lund and Stockholm, between 2000 and 2014, assessing time to the first event within 1 month or 1 year. We analysed differences in the number of and the time to events between the preterm and term cohort using the Kaplan–Meier survival curve, a generalised model applying zero-inflated Poisson distribution and Gary-Anderson’s method.Results:Overall, 413 children were included in the study. Of these, 93 (22.5%) were born prematurely. The total number of adverse events was 178 (110 minor and 68 major). There was no difference between the cohorts in the number of events, whether within 1 month or within a year, between major (p = 0.69) and minor (p = 0.84) events or frequencies of multiple events (p = 0.92).Conclusion:Despite earlier procedural age, larger atrial septal defects, and higher comorbidity than term children, preterm children appear to have comparable risk for complications during the first year after surgical or percutaneous closure.

show abstract

Section: Discussionmentioning

confidence: 99%

Adverse events within 1 year after surgical and percutaneous closure of atrial septal defects in preterm children

et al. 2019

View full text Add to dashboard Cite

show abstract

“…On the other hand, our institution did not experience serious complications after trans-catheter device closure, such as erosion of aortic Valsalva, cardiac perforation, or late cardiac tamponade [4,[6][7][8][9]. These favorable outcomes were provided by the presence of technically sophisticated cardiac catheter interventionists and their careful selection of patients and devices.…”

Section: Discussionmentioning

confidence: 93%

“…Moreover, its cosmetic superiority is another attractive advantage for children and adult females. On the contrary, late significant complications could occur after transcatheter device closure, and outcomes of surgical closure required after trans-catheter device closure are significantly worse, as opposed to that after primary surgical closure [4,[6][7][8][9][10][11]. Therefore, collaboration of cardiac catheter interventionists and surgeons is more essential to treat patients with ASD in the current era.…”

mentioning

confidence: 99%

Management of ostium secundum atrial septal defect in the era of percutaneous trans-catheter device closure: 7-Year experience at a single institution

Hoashi

Yazaki

Kagisaki

et al. 2015

Journal of Cardiology

View full text Add to dashboard Cite

Percutaneous trans-catheter ASD closure was safely performed under the support of a surgical team. The cosmetic outcome of surgical closure is improving after initiation of partial sternotomy via limited skin incision for the pediatric population and young adult females. Prior to the treatment, the physicians must thoroughly inform patients and families of the advantages and disadvantages of both treatment options.

show abstract

“…It is more serious that residual septal defects are frequently associated with surgery-related side-effect complications, such as reoperation, infection, sternotomy scarring, and even death ( Gaynor et al, 2001 ; Oses et al, 2010 ). To avoid those side effects of surgery, interventional closure has been developed to the main treatment to septal defects ( Huang et al, 2013 ; Shimpo et al, 2013 ; Morray, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices

Tang

Yue-jin

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Atrial septal defects (ASDs) are the most common types of cardiac septal defects in congenital heart defects. In addition to traditional therapy, interventional closure has become the main treatment method. However, the molecular events and mechanisms underlying the repair progress by occlusion device remain unknown. In this study, we aimed to characterize differentially expressed genes (DEGs) in the blood of patients treated with occlusion devices (metal or poly-L-lactic acid devices) using RNA-sequencing, and further validated them by qRT-PCR analysis to finally determine the expression of key mediating genes after closure of ASD treatment. The result showed that total 1,045 genes and 1,523 genes were expressed differently with significance in metal and poly-L-lactic acid devices treatment, respectively. The 115 overlap genes from the different sub-analyses are illustrated. The similarities and differences in gene expression reflect that the body response process involved after interventional therapy for ASDs has both different parts that do not overlap and the same part that crosses. The same portion of body response regulatory genes are key regulatory genes expressed in the blood of patients with ASDs treated with closure devices. The gene ontology enrichment analysis showed that biological processes affected in metal device therapy are immune response with CXCR4 genes and poly-L-lactic acid device treatment, and the key pathways are nuclear-transcribed mRNA catabolic process and proteins targeting endoplasmic reticulum process with ribosomal proteins (such as RPS26). We confirmed that CXCR4, TOB1, and DDIT4 gene expression are significantly downregulated toward the pre-therapy level after the post-treatment in both therapy groups by qRT-PCR. Our study suggests that the potential role of CXCR4, DDIT4, and TOB1 may be key regulatory genes in the process of endothelialization in the repair progress of ASDs, providing molecular insights into this progress for future studies.

show abstract

Transcatheter closure of secundum atrial septal defect

Cited by 4 publications

References 47 publications

Adverse events within 1 year after surgical and percutaneous closure of atrial septal defects in preterm children

Adverse events within 1 year after surgical and percutaneous closure of atrial septal defects in preterm children

Management of ostium secundum atrial septal defect in the era of percutaneous trans-catheter device closure: 7-Year experience at a single institution

Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices

Contact Info

Product

Resources

About